Influenza virus neuraminidase inhibitors

Lancet

Volumn 355, Issue 9206, 2000, Pages 827-835

  Gubareva, Larisa V ^a   Kaiser, Laurent ^a   Hayden, Frederick G ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; OSELTAMIVIR; PERAMIVIR; RIMANTADINE; RWJ 270701; SIALIDASE; SIALIDASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS PROTEIN; ZANAMIVIR;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; COUGHING; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG BIOAVAILABILITY; DRUG RESISTANCE; DRUG TARGETING; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INFLUENZA; INFLUENZA VIRUS A; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SORE THROAT; VERTIGO; VIRUS REPLICATION; VIRUS TRANSMISSION; WHEEZING;

EID: 0034603350     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(99)11433-8     Document Type: Review

References (69)

1. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993; 363: 418-23.
2. Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc 1997; 119: 681-90.
3. Calfee DP, Hayden FG. New approaches to influenza chemotherapy: neuraminidase inhibitors. Drugs 1998; 56: 537-53.
4. Kim CU, Chen X, Mendel DB. Neuraminidase inhibitors as anti-influenza virus agents. Antiviral Chem Chemother 1999; 10: 141-54.
5. Laver WG, Bischofberger N, Webster RG. Disarming flu viruses. Sci Am 1999; 280: 78-87.
6. Varghese JN, Colman PM. Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2.2 Å resolution. J Mol Biol 1991; 221: 473-86.
7. Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol 1993; 67: 2972-80.
8. Goto H, Kawaoka Y. A novel mechanism for the acquisition of virulence by a human influenza A virus. Proc Natl Acad Sci USA 1998; 95: 10224-28.
9. Li W, Escarpe PA, Eisenberg EJ, et al. Identification of GS4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS4071. Antimicrob Ag Chemother 1998; 42: 647-53.
10. Gubareva LV, McCullers JA, Bethall RC, Webster RG. Characterization of influenza A/HongKong/156/97 (H5N1) virus in a mouse model and protective effect of zanamivir on H5N1 infection in mice. J Infect Dis 1998; 178: 1592-96.
11. Leneva IA, Roberts N, Webster RG. Efficacy of oseltamivir on H5N1 and H9N2 influenza viruses. II International Symposium on Influenza and other Respiratory Viruses (Dec 10-12, 1999, Grand Cayman); abstr.
12. Hay AJ. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Semin Virol 1992; 3: 21-30.
13. Hayden FG. Amantadine and rimantadine - clinical aspects. In: Richman DD, ed. Antiviral drug resistance. Chichester: Wiley, 1996: 59-77.
14. Staschke KA, Colacino JM, Baxter AJ, et al. Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en. Virology 1995; 214: 642-46.
15. Gubareva LV, Bethell R, Hazt GJ, et al. Generation and characterisation of mutants of influenza A virus selected with the neuraminidase inhibitor 4-guanidino-Neu5Ac2en. J Virol 1996; 70: 1818-27.
16. Tai CY, Escarpe PA, Sidwell RW, et al. Characterization of human influenza virus variants selected in vitro in the presence of the neuraminidase inhibitor GS 4071. Antimicrob Ag Chemother 1998; 42: 3234-41.
17. Blick TJ, Tiong T, Sahasrabudhe A, et al. Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en. Virology 1995; 214: 475-84.
18. Mendel DB, Sidwell RW. Influenza virus resistance to neuraminidase inhibitors. Drug Resistance Updates 1998; 1: 184-89.
19. McKimm-Breschkin JL, Sahasrabudhe A, Blick TJ, et al. Mutations in a conserved residue in the influenza virus neuraminidase active site decreases sensitivity to Neu5Ac2en-derived inhibitors. J Virol 1998; 72: 2456-62.
20. McKimm-Breschkin JL, McDonald M, Blick TJ, Colman PM. Mutation in the influenza virus neuraminidase gene resulting in decreased senitivity to the neuraminidase inhibitor-4-guanidino-Neu5Ac2en leads to instability of the enzyme. Virology 1996; 225: 240-42.
21. Gubareva LV, Robinson MJ, Bethell RC, Webster RG. Catalytic and framework mutations in the neuraminidase active site of influenza viruses that are resistant to 4-guanidino-Neu5Ac2en. J Virol 1997; 71: 3385-90.
22. Colacino JM, Garman E, Chirgadze NY, et al. A single sequence change destabilizes the influenza virus neuraminidase tetramer. Virology 1997; 236: 66-75.
23. Ives J, Caar J, Roberts N, et al. An oseltamivir-treatment selected influenza A/N2 virus with an R292K mutation in the neuraminidase gene has reduced infectivity in vivo. II International Symposium on Influenza and Other Respiratory Viruses (Dec 10-12, 1999, Grand Cayman); abstr.
24. Blick TJ, Sahasrabudhe A, McDonald M, et al. The interaction of neuraminidase and hemagglutinin mutations in influenza virus in resistance to 4-guanidino-Neu5Ac2en. Virology 1998; 246: 95-103.
25. Gor D, Cadman A, Dempsey M, et al. Antiviral efficacy and sequence analysis of HA and NA genes of influenza isolates from zanamivir phase II/III clinical efficacy trials. 39th ICAAC (San Francisco, September, 1999); abstr 284.
26. Boivin G, Goyette N, Aoki FY, Wagner A, Trottier S. Clinical and virological efficacy of zanamivir in the treatment of influenza A virus infections during the 1997-98 flu season. 39th ICAAC (San Francisco, September, 1999); abstr 289a.
27. Gubareva LV, Matrosovich MN, Brenner MK, Bethell R, Webster RG. Evidence for zanamivir resistance in an immun o compromised child infected with influenza B virus. J Infect Dis 1998; 178: 1257-62.
28. Covington E, Mendel DB, Escarpe PA, Tai CY, Soderbarg K, Roberts NA. Phenotypic and genotypic assay of influenza virus neuraminidase indicates a low incidence of viral drug resistance during treatment with oseltamivir. II International Symposium on Influenza and other Respiratory Viruses (Dec 10-12, 1999, Grand Cayman); abstr.
29. Calfee DP, Peng AW, Hussey EK, Lobo M, Hayden FG. Safety and efficacy of once daily intransal zanamivir in preventing experimental human influenza A infection. Antiviral Ther 1999; 4: 143-49.
30. Cass L, Brown J, Pickford M, et al. Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers. Clin Pharmacokinet 1999; 36: 21-31.
31. Peng AW. Sustained concentration in respiratory tract after 10 mg zanamivir (ZMV) inhalation. 39th ICAAC (San Francisco, Sept, 1999); abstr 46.
32. Cass L, Efthymiopoulos C, Bye A. Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers. Clin Pharmacokinet 1999; 36: 1-11.
33. Wood ND, Aitken M, Sharp S, Evison H. Tolerability and pharmacokinetics of the influenza neuraminidase inhibitor Ro-64-0802 (GS4071) following oral administration of the prodrug Ro-64-0796 (GS4104) to health male volunteers. 37th ICAAC (Toronto, 1997); abstr A-123.
34. Roche Pharmaceutic als Laboratories. Tamiflu package insert (Oct 27, 1999).
35. Eisenberg G, Bidgood A, Lynch G, Lee WA, Cundy K. Penetration of GS4071, a novel influenza neuraminidase inhibitor, into rat bronchoalveolar lining fluid following oral administration of the prodrug GS4104. Antimicrob Ag Chemother 1997; 41: 1949-52.
36. Freund B, Gravenstein S, Elliott M, Miller I. Zanamivir: a review of clinical safety. Drug Safety 1999; 21: 267-81.
37. Daniel MJ, Barnett JM, Pearson BA. The low potential for drug interactions with zanamivir. Clin Pharmacokinet 1999; 36: 41-50.
38. Webster A, Boyce M, Edmunson S, Miller I. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers. Clin Pharmacokinet 1999; 36: 51-58.
39. Cass L, Gunawardena K, MacMahon M, Bye A. Pulmonary function and airway responsiveness in mild to moderate asthmatics given repeated inhaled doses of zanamivir. Resp Med (in press).
40. US Food and Drug Administration. Public health advisory: safe and appropriate use of influenza drugs (Jan 12, 2000).
41. Hayden FG, Atmar RL, Schilling M, et al. Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 1999; 341: 1336-43.
42. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza. JAMA 1999; 282: 1240-46.
43. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996; 275: 295-99.
44. Hayden FG, Lobo M, Hussey EK, Eason CU. Efficacy of intranasal GG167 in experimental human influenza A and B virus infection. In: Brown LE, Hampson AW, Webster RG, eds. Options for the control of influenza. Amsterdam: Elsevier, 1996: vol III, 718-25.
45. Hayden FG, Robinson R, Jennings L, et al. Efficacy of oral oseltamivir in experimental human influenza B virus infection. IDSA '98 (Philadelphia, Nov 18-21, 1999); 157 abstr.
46. Calfee DP, Peng AW, Cass L, Lobo M, Hayden FG. Safety and efficacy of intravenous zanamivir in preventing experimental human influenza A virus infection. Antimicrob Ag Chemother 1999; 43: 1616-20 (abstr).
47. Fritz RS, Hayden FG, Calfee DP, et al. Nasal cytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-controlled trial of intravenous zanamivir treatment. J Infect Dis 1999; 180: 586-93.
48. Walker JB, Hussey EK, Treanor JJ, Montalvo A, Hayden FG. Effects of the neuraminidase inhibitor zanamivir on otologic manifestations of experimental human influenza. J Infect Dis 1997; 176: 1417-22.
49. Hayden FG, Osterhaus ADME, Treanor JJ, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza virus infections. N Engl J Med 1997; 337: 874-79.
50. Monto AS, Fleming DM, Henry D, et al. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. J Infect Dis 1999; 180: 254-61.
51. MIST Study Group. Randomized trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. Lancet 1998; 352: 1877-81.
52. Fleming D, Makela M, Pauksens K, Man C, Webster A, Keene O. "High risk" and otherwise healthy patients demonstrate alleviation of influenza symptoms 2.5 days earlier following inhaled zanamivir treatment: European study, winter 1997/98. IDSA '98 (Denver, Nov 12-15, 1998); abstr 789.
53. Lalezari J, Klein T, Stapleton JT, Elliott M, Flack N, Keene O. The efficacy and safety of inhaled zanamivir in the treatment of influenza in otherwise healthy and 'high risk' individuals in North America. J Antimicrob Chemother 1999; 44: 42 (abstr).
54. Osterhaus AD, Makela M, Webster A, Keene O. The efficacy of inhaled zanamivir in the treatment of influenza B. 39th ICAAC (San Francisco, September, 1999); abstr 281.
55. Kaiser L, Hayden FG, Hammond J, Keene O. Efficacy of inhaled zanamivir in reducing complications and antibiotic use in influenza: results of phase II and III clinical studies. 39th ICAAC (San Francisco, September, 1999); abstr 1903.
56. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza. JAMA 2000; 283: 1016-24.
57. Aoki FY, Osterhaus AD, Rimmelzwaan GF, Kinnersley N, Ward P. Oral GS4104 successfully reduces duration and severity of naturally acquired influenza. 38th ICAAC (San Diego, 1998); abstr LB-5.
58. Oxford JS, Ward P, Kinnersley N. Influenza treatment with oral oseltamivir reduces viral load and antibiotic use related to respiratory complications. Eur Resp J 1999; 14: 254s (P1722) (abstr).
59. Nicholson KG, Ward P, Kinnersley N. Oral GS4104 in the treatment of influenza in adults is effective and reduces influenza-related complications and need for antibiotic treatment. J Antimicrob Chemother 1999; 44: 41-42 (abstr).
60. Monto AS, Robinson DP, Herlocher L, Hinson JM, Elliott M, Crisp A. Zanamivir in the prevention of influenza among healthy adults. JAMA 1999; 282: 31-36.
61. Hayden FG, Gubareva LV, Klein T, et al. Inhaled zanamivir for preventing transmission of influenza in families. 39th ICAAC (September, 1999, San Francisco); abstr LB29.
62. Kaiser L, Henry D, Flack N, Keene O, Hayden FG. Short-term zanamivir to prevent influenza: results of a placebo controlled study. Clin Infect Dis (in press).
63. Peters PH, Norwood P, DeBock V, et al. Oseltamivir is effective in the longterm prophylaxis of influenza in vaccinated frail elderly. II International Symposium on Influenza and other Respiratory Viruses (Dec 10-12, 1999, Grand Cayman); abstr.
64. Oxford J, Jackson H. Short-term prophylaxis with oral oseltamivir effectively prevents spread of influenza A and B. II International Symposium on Influenza and other Respiratory Viruses (Dec 10-12, 1999, Grand Cayman); abstr.
65. Lee C, Loeb M, Phillips A, et al. Use of zanamivir (AZ) to control an outbreak of influenza A (Flu A). 39th ICAAC (San Francisco, September, 1999); abstr 283.
66. Gravenstein S, Freund B, McElhaney JE, Schilling M, Keene O. Greater effectiveness from zanamivir treatment of influenza with antecedent influenza vaccination in older patients. 39th ICAC (San Francisco, September, 1999); abstr 1902.
67. Monto AS, Webster A, Keene O. Randomised, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. J Antimicrob Chemother 1999; 44: 23-29.
68. Gubareva LV, Schallon D, Hayden FG. Activity of the neuraminidase inhibitor RWJ-270201 (BCX-1812) against influenza A and B viruses in the neuraminidase inhibition assays. II International Symposium on Influenza and other Respiratory Viruses (Dec 10-12, 1999, Grand Cayman); abstr.
69. Bantia S, Ananth SL, Andries K, Horn K, Parker C, Chand P. In vitro activity of the neuraminidase inhibitor RWJ-270201 (BCX-1812) against influenza virus. 39th ICAAC (San Francisco, September, 1999); abstr 947.